Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes

NCT02380521 on ClinicalTrials.gov · last registry update 2016-11-08

Finished July 2016, after enrolling 60 people. Primary outcome, as filed: Subclinical atherosclerosis (as measured by cIMT) in patients with T2DM treated with exenatide once weekly. exenatide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P4
Drug: exenatide
Bydureon, Byetta
Sponsor: University of Palermo
Sponsor type: Other
Enrollment: 60
Started: 2015-01
Primary completion: 2016-07 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Subclinical atherosclerosis (as measured by cIMT) in patients with T2DM treated with exenatide once weekly

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.